A Randomised, Double Blind Study to Evaluate the Safety and Efficacy of the p38 Kinase Inhibitor, GW856553, in Subjects With Neuropathic Pain From Peripheral Nerve Injury
Phase of Trial: Phase II
Latest Information Update: 20 Feb 2017
At a glance
- Drugs Losmapimod (Primary)
- Indications Neuropathic pain
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 24 Mar 2012 This trial is 'recruiting' in Spain.
- 28 May 2010 Planned end date changed from 1 Dec 2010 to 1 Oct 2010 as reported by ClinicalTrials.gov.
- 28 May 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.